Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.09M | 53.43M | 54.35M | 52.92M | 52.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.09M | 53.43M | 54.35M | 52.92M | 52.12M |
| Cost of Revenue | 48.02M | 48.22M | 48.79M | 47.55M | 47.05M |
| Gross Profit | 4.07M | 5.21M | 5.56M | 5.38M | 5.07M |
| SG&A Expenses | 3.49M | 3.52M | 3.54M | 3.54M | 3.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.51M | 51.73M | 52.33M | 51.09M | 50.68M |
| Operating Income | 577.00K | 1.69M | 2.02M | 1.83M | 1.45M |
| Income Before Tax | 695.00K | 1.75M | 2.06M | 1.88M | 1.46M |
| Income Tax Expenses | 901.00K | 1.08M | 1.25M | 627.00K | 527.00K |
| Earnings from Continuing Operations | -0.21 | 0.67 | 0.81 | 1.25 | 0.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -206.00K | 672.00K | 808.00K | 1.25M | 928.00K |
| EBIT | 577.00K | 1.69M | 2.02M | 1.83M | 1.45M |
| EBITDA | 879.00K | 2.00M | 2.34M | 2.15M | 1.77M |
| EPS Basic | -0.01 | 0.02 | 0.03 | 0.04 | 0.03 |
| Normalized Basic EPS | 0.01 | 0.04 | 0.04 | 0.04 | 0.03 |
| EPS Diluted | -0.01 | 0.02 | 0.03 | 0.04 | 0.03 |
| Normalized Diluted EPS | 0.01 | 0.04 | 0.04 | 0.04 | 0.03 |
| Average Basic Shares Outstanding | 123.03M | 122.15M | 121.19M | 120.67M | 120.47M |
| Average Diluted Shares Outstanding | 124.61M | 124.85M | 124.08M | 124.17M | 123.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |